Skip to content
Open Data Finder
Open Government Canada

Literature Review on the Immunogenicity of Herpes Zoster Vaccines

Published by Public Health Agency of Canada | Agence de la santé publique du Canada

About this dataset

Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.

Literature Review on the Immunogenicity of Herpes Zoster Vaccines · Open Data Finder